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Abstract: Sickle cell disease (SCD) is common throughoutmuchof sub-SaharanAfrica, affecting up
to 3% of births in some parts of the continent. Nevertheless, it remains a low priority formany health
ministries. The most common form of SCD is caused by homozygosity for the -globin S gene
mutation (SS disease). It is widely believed that this condition is associated with very high child
mortality, but reliable contemporary data are lacking. We have reviewed available African data on
mortality associated with SS disease from published and unpublished sources, with an emphasis on
two types of studies: cross-sectional population surveys and cohort studies.We have concluded that,
although current data are inadequate to support defınitive statements, they are consistent with an
early-life mortality of 50%–90% among children born in Africa with SS disease. Inclusion of SCD
interventions in child survival policies and programs in Africa could benefıt from more precise
estimates of numbers of deaths among children with SCD. A simple, representative, and affordable
approach to estimate SCD child mortality is to test blood specimens already collected through large
population surveys targeting conditions such as HIV, malaria, and malnutrition, and covering
children of varying ages. Thus, although there is enough evidence to justify investments in screening,
prophylaxis, and treatment for African children with SCD, better data are needed to estimate the
numbers of child deaths preventable by such interventions and their cost effectiveness.
(Am J Prev Med 2011;41(6S4):S398–S405) © 2011 American Journal of Preventive Medicinea
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iIntroduction
In Africa, sickle cell disease (SCD) is reported to beassociated with a very high rate of childhoodmortal-ity, 50%–90%, yet there is a lack of reliable, up-to-
ate information.1–9 Themost frequently cited study was
conducted in the Garki district in rural northern Nigeria
in the early 1970s.10–12 This Garki study provided valu-
ble information on child survival and other aspects of
he natural history of SCDduring early childhood for that
rea about 40 years ago, but current, up-to-date informa-
ion on the burden of mortality from SCD in Africa
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reatments and preventive interventions is lacking.
Quantifying the number of under-5 child deaths from
CD in African countries is important to attract policy
upport and resources for measures to reduce the burden
f mortality. Elevated mortality due to SCD among chil-
ren younger than 5 years has been virtually eliminated
rom North America through a number of simple inter-
entions, including newborn screening and prevention of
nfection through the provision of penicillin prophylaxis
nd polyvalent pneumococcal vaccination.13,14 Even in
he absence of these therapies, health education (e.g.,
aising awareness of fever and of splenic sequestration)
as been demonstrated to be effective in reducing SCD
ortality in young children.15–17 Moreover, a pilot pro-
ram in Benin has shown that with newborn screening
nd good follow-up care, it is likewise possible to reduce
ortality among African children with SCD to the same
evel as other children.18 One of the major challenges in
valuating the cost effectiveness of newborn screening for
CD is the lack of adequate data on the numbers of deaths
n unscreened cohorts.19,20
The 63rd session of the UN General Assembly in De-
cember 2008 adopted a resolution on the “recognition of
sickle-cell anaemia as a public health problem,” and
urged Member States and UN organizations to raise
©2011American Journal of PreventiveMedicine. All rights reserved.
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Dawareness of SCD on June 19 of each year.21 Despite the
act that the UN has called for global efforts “to bring the
isease out of the shadows,” relatively little attention has
een given to assessing the burden of SCD and how to
educe it inAfrica,where about 85%of childrenwith SCD
re born.22 In 2010, the WHO Regional Offıce for Africa
proposed a SCD strategy in offıcial recognition of the fact
that this disease is an important cause of child mortality
inmany African countries.23 Enough is already known to
ustify investment in public health SCD programs, such
s those already in place for other conditions (e.g., HIV or
alaria), for promoting widespread screening, health ed-
cation, and treatment to prevent or manage SCD
omplications.
The Classification of Sickle Cell Disease
The most common subtype of SCD worldwide is ho-
Figure 1. Map of the distribution of the S gene in Africa
Note: The map is based on representative indigenous population sam
in Piel et al.24 The figure shows the global distribution of the sickle c
f the malaria hypothesis.mozygous SCD, characterized by the presence of two
ecember 2011copies of the -globin S
(S) mutation that codes
for sickle cell hemoglo-
bin (Hb S). Homozygous
SCD is variably referred
to as sickle cell anemia,
Hb SS, SS, SS disease, or
sickle cell disease-SS. The
distribution of the S al-
lele (Figure 1) has re-
cently been mapped
globally using detailed
geo-referenced data and
displays a close associa-
tion with the historical
distribution of Plasmo-
dium falciparum malar-
ial endemicity.24 Within
Africa, the frequency of
S, and accordingly SS, is
highest in low-altitude
equatorial regions. The sec-
ond subtype of SCD com-
moninAfrica iscompound
heterozygosity for S and
C (SC). The C allele is
found almost exclusively
among people of West
African ancestry, being
most common among
those in Burkina Faso
and northern Ghana.
Compound heterozygos-
ity with -thalassemia
(S-thalassemia) is a
form of SCD that is believed to be rare in most of sub-
Saharan Africa.12 In Central, East, and Southern Africa,
SCD is generally assumed to be synonymous with SS
disease, although few studies have specifıcally looked for
S0-thalassemia.
Mortality and Sickle Cell Disease in Africa
Reports of high rates of childhood mortality, 50%–90%,
among African children with SCD are specifıc to
SS.1–7,10–12 Qualitatively, experts have stated that the
majority,”25 “most,”20,26 the “vastmajority,”27 or “nearly
all”28 Africans born with SS die during childhood. From
the 1950s onward, multiple researchers have reported an
almost total absence of SS among samples of African
adults,10,29–33 whereas other investigators have reported
fınding a frequency of SS among African adults of repro-
and is adapted from Figure 1b
ne and geographic confirmationples
ell geductive age of up to 20% of the expected number.34–38
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of raised mortality has been reported in some studies,39
but not in others.40
The purposes of this review are: (1) to describe the
methods that can be used to estimate SCD mortality;
(2) to assess the available data on child survival among SS
individuals in Africa; and (3) to discuss prospects for
improving the current estimates through the collection
and analysis of additional data. We reviewed and inter-
preted recent data that could provide insights into the
current rates of survival among children with SCD in
Africa, much of which has not been cited in previous
expert discussions.
Approaches to Estimating Mortality
Two basic epidemiologic approaches can be used to as-
sess mortality among children with SCD or any other
congenital condition. The fırst is a prospective cohort
design in which a representative sample of infants are
recruited in early life and are then followed to assess their
subsequent risk of death. Such studies “are expensive and
time-consuming”41 and, therefore, are relatively uncom-
mon. The second approach to estimating mortality
among patientswith SCD is to collect cross-sectional data
on children of various ages and compare the frequencies
of hemoglobin genotypes across age groups. To the extent
that children with SS experience excess mortality relative
to children with other genotypes, the frequency of that
genotype will decrease progressively with age.41
Because the number of infants included in cross-
sectional surveys typically is too small for precise esti-
mates of the frequency of SS, an alternative is to use
estimates of the frequency of the S allele among the
opulation, together with the Hardy-Weinberg equi-
ibrium (HWE) formula, to estimate the frequency of
S at birth.22,38 This method assumes either random
ating or the availability of data on the population
oeffıcient of consanguinity. It also assumes that data
re available on heterozygosity frequencies at birth, or
hat the heterozygous state does not markedly influ-
nce overall survival. Although the sickle cell trait or
arrier state (AS) can reduce the risk of severe P. falci-
arummalaria by roughly 90%42 and is associated with
educed all-cause mortality at aged 2–16 months,43 the
prevalence of AS does not appear to be signifıcantly
affected as a result of the heterozygote advantage.11
Leaving aside those complications, the HWE formula
in regard to S and C, the major alleles that contribute
o SCD, is represented by Equation 1:p2 2pq q2 2pr r2 2qr 1 (1) Bfor 2 and 3 alleles, where pA allele frequency; qS
allele frequency; rC allele frequency, and 2pq, 2pr, and
qr are the frequencies of AS, AC, and SC, respectively.
If there are only two alleles present, it is possible to
alculate the expected frequency of SS (q2) from the ob-
served frequency of AS (2pqn) using Equation 2:
q
11 Zn
Z
. (2)
For example, among a population in which the observed
prevalence of AS (n) is 20.0%, and no other hemoglobin
variants are present, on the basis of HWE, it is estimated
that the S allele frequency (q) is 0.113, and the expected
requency of SS (q2) is 1.27% (Table 1).
Prospective Cohort Studies
A major limitation of prospective cohort studies for as-
sessing the population probability of survival is that if
medical follow-up is offered for children diagnosed with
SCD, survival is likely to be much higher than that expe-
rienced by children with SCD in the population.41 This is
likely to occur even if children are not prospectively
screened for SCD, because of the close medical attention
received by all children in prospective clinical studies.
Five prospective cohort studies involving infants in
Africa with SCD were identifıed. Two older studies did
not report systematic follow-up nor complete data on
survival.11,42 Two recent studies with systematic follow-
p, one each from Kenya43 and Ghana,44 both reported
ittle or no excess mortality among children with SS rela-
ive to children with other genotypes. First, the Asembo
Table 1. Predicted SS and S allele frequency, based on
arious observed Hb AS genotype frequencies,
ssuming HWE
AS frequency
(%, obs.)
SS frequency
(%, HWE)
S frequency
(HWE)
5.0 0.07 0.026
10.0 0.28 0.053
15.0 0.67 0.082
20.0 1.27 0.113
25.0 2.14 0.146
30.0 3.38 0.184
35.0 5.11 0.226
40.0 7.64 0.276
AS, sickle cell trait; S, -globin S; Hb, hemoglobin; HWE, Hardy-
Weinberg equilibrium; obs., observed; SS, sickle cell anemiaay Cohort Project in Kisumu, Kenya,43 during 1992–
www.ajpmonline.org
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D1994 retrospectively genotyped specimens and reported
mortality for children with hemoglobin genotypes AA,
AS, and SS. A total of 1022 children were followed pro-
spectively, of whom 1002 were genotyped. Overall, the
cumulative probability of survival to age 6 years adjusted
for maternal survival and gestational age was 75% among
children with SS, compared with 78% among children
with AA and 81% among children with AS. Second,
Kreuels et al.44 prospectively recruited 1070 Ghanaian
infants aged 2–4months during 2003 and followed 852 of
them to age 23 months. A total of 19 children died, none
of them with either SS or SC.
In urban Guinea-Bissau, infants at age 6 months were
monitored for a prospective cohort study, and at age
18months, 1057 of themwere genotyped for hemoglobin
variants.45 The authors identifıed 50 (4.7%) heterozy-
otes and 2 (0.2%) homozygotes, consistent with an ex-
ected SS frequency of 0.1% based onHWE. The children
ubsequently were followed through age 4 years, and
either child with SS died.
Other prospective cohort studies have enrolled pa-
ients of various ages at SCD clinics, an approach that
oes not provide information on survival from birth. For
xample, Makani et al.8 reported data on 169 children
with SS younger than age 2 years attending a large SCD
clinic inDar-es-Salaam,Tanzania, amongwhom2 (1.0%)
deaths were recorded. The low rate of mortality was con-
sistent with the observations of Aidoo et al.43 and Kreuels
et al.44 of low mortality among young children with SS
who are enrolled in high-quality prospective research
studies.
Age-Stratified Cross-Sectional Surveys
The use of cross-sectional survey data to assess the bur-
den of SCDmortality is not new,38 although only a hand-
ful of African studies have compared prevalence rates
across age groups (Figure 2; Table 2). For example, Bar-
clay46 reported that among 7569 children in a Zambian
ining town, the frequency of SS decreased from 1.3%
mong 2845 infants to 0.9% among 2200 children aged
–3 years, and to 0.5% among 2306 children aged
–12 years, an apparent excess mortality of 60% relative
o children with other genotypes (AA and AS together),
alculated as (1.30.5)/1.3.
The Garki study that, as previously discussed, is cited
idely in the context of discussions on SCD mortality,12
examined 534 newborns and 896 other children aged
1–14 years in a rural part of Kano State, Nigeria, in the
early 1970s. The authors reported that the frequency of SS
was 2.1% among newborns (11/534); 0.4% (1/259) at age
1–4 years; and 0.2% (1/637) at age 5–14 years.10,11 Those
fıgures indicated a 92% cumulative excess mortality rate
ecember 2011through age 15 years for those with SS relative to those
with AA or AS. In a subsequent review, Fleming stated
that at “5 years and above less than 2% of the expected
numbers of subjects with Hb SS” were alive.12 However,
that does not mean that 98% of subjects with SS disease
died before the age of 5, as is often stated, because adults
aswell as childrenwere included in the denominator. The
probability of death before age 5 years can be calculated
only through estimation of survival curves showing the
percentage alive at each exact age, and that requires larger
numbers of observations.
Recently published survey data from Kilifı district in
coastal Kenya also reported a low frequency of SS in age
groups beyond infancy.25,41 Among 1480 healthy control
articipants younger than age 5 years, McAuley et al.25
found a frequency of 1.0% SS (8 of 782) among infants
aged 0–11 months and 0.3% (2 of 697) among children
aged 12–59 months. In combination with data from the
same cohort reported byWilliams et al.,41 three (0.1%) of
261 children aged 6–13 years had SS. The frequency
f AS among children aged 0–59months was 14.7% (218
f 1480),25 and according to HWE, the predicted fre-
uency of SS was 0.64%. Therefore, the proportionate
efıcit among those in the group aged 6–13-years was
pproximately 85%.
Danquah et al.47 recently reported that among 2108
children younger than age 10 years in the Northern re-
gion of Ghana, the frequencies of AS and SS were 7.4%
and 0.3%, respectively, consistent with HWE. The age-
specifıc fındings, which were shared in a personal com-
munication (FP Mockenhaupt, Institute for Tropical
Medicine, Berlin, personal communication, February 9,
2011), indicated that the frequency of SS was 0.39%
1 2 3 4 5 6 7 8 9 10 11 12
0
0.5
1
1.5
2
2.5
Garki study10
Kilifi study41
Barclay (1971)46
Age (years) 
P
er
ce
nt
ag
e 
H
bS
S
 
Figure 2. Prevalence of Hb SS by age among children in
three African studies
Note: The studies are Fleming et al.10 (Garki, Nigeria), Williams et
l.41 (Kilifi, Kenya), and Barclay46 (Zambia).
b SS, sickle cell anemiaamong 1266 children younger than age 5 years and 0.12%
S402 Grosse et al / Am J Prev Med 2011;41(6S4):S398–S405among 842 children aged 5–9 years. These data sug-
gested, therefore, an approximate 70% defıcit of SS
among children older than age 5 years. However, because
of the low frequency of the S allele in northern Ghana,
the study was too small to yield reliable estimates of age
differences in prevalence.
Other Cross-Sectional Surveys
Other cross-sectional surveys of hemoglobin variants
among African populations have compared the ob-
served prevalence of SS relative to that which would be
expected based on the frequency of the S allele and
HWE. In Burkina Faso, Simpore et al.40 found 12
(0.13%) homozygotes among 9201 individuals
Table 2. Frequency of Hb SS by age group: selected cros
Study Study location Study years
Barclay
(1971)46
Zambia (mining town) 1969–1971
Fleming et al.
(1979)10
Nigeria (rural Garki) 1970–1972
McAuley et al.
(2010),25
Williams et
al. (2009)41
Kenya (Kilifi) 1998–2008
Danquah et
al. (2010)47
Ghana (Northern Region) 2002
Simpore et al.
(2002)40
Burkina Faso 1997–1999
Desai et al.
(2005)48
Kenya (rural Bondo) 1998–1999
Allen
(1992)49
The Gambia (rural) 1988
Cox et al.
(2008)50
The Gambia (rural) 2003
Sarr et al.
(2006)51
Senegal (rural Niakhar) 2002–2003
Saurin
(1984)52
Senegal (rural
Kégoudou)
1970–1978
Hb SS, sickle cell anemia; HWE, Hardy-Weinberg equilibriumscreened during 1997–1999, consistent with a defıcit inthe numbers of people with SS of approximately 50%
relative to the number expected based on HWE with
frequencies of AS and SC of 8.1% and 1.5%, respec-
tively. In western Kenya, Desai and colleagues48 geno-
typed almost 1900 children younger than age 36
months during 1998–1999 and found frequencies of
AS and SS of 22.0% and 0.6%, respectively. The ex-
pected frequency of SS was 1.6%, which suggest that
approximately 60% of the children born with SS
in the communities surveyed by Desai et al. had died
prior to the health surveys. Finally, four small cross-
sectional studies from rural populations in The Gam-
bia and Senegal are also summarized in Table 2. The
pooled prevalence of SS in the four studies49–52 was
ctional studies
e groups N SS (%) Comments
1 months 2845 1.3 60% excess mortality by
age 12 years
years 2200 0.9
2 years 2306 0.5
borns 534 2.1 92% excess mortality
past age 5 years
years 259 0.4
4 years 637 0.2
1 months 782 1.0 90% excess mortality by
age 13 years
23 months 282 0.35
years 415 0.24
3 years 3677 0.09
years 1266 0.39 70% excess mortality
past age 5 years
0 years 842 0.12
borns HWE 0.25 Data consistent with 50%
excess mortality
ian 9
ars
9201 0.13
borns HWE 1.6 Data consistent with 62%
excess mortality prior
to the surveysyears 2774 0.6
borns HWE 1.2 Data consistent with 75%
excess mortality
years 389 0.3
borns HWE 0.8 Data consistent with 67%
excess mortality
72 months 536 0.3
borns HWE 0.5
0 years 432 None
borns HWE 1.0 At least 70% excess
mortality, but no
information by what
age
ges 596 0.3s-se
Ag
0–1
1–3
3–1
New
1–4
5–1
0–1
12–
3–5
6–1
0–4
5–1
New
Med
ye
New
0–3
New
3–8
New
10–
New
2–1
New
All aapproximately 75% lower than the expected frequency
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Dof homozygotes based onHWE. It should be noted that
these studies were conducted in isolated rural commu-
nities, and it is not possible to draw conclusions about
survival probabilities in a country in the absence of
national-level survey data.
Discussion
To sum up, most studies that have included data about
child survival among unselected or nonclinical sam-
ples of African children have suggested that the major-
ity of those with SS died during early childhood, as
indicated by the substantial defıcit of SS among sam-
ples of older children or adults. However, most pub-
lished information comes from rural areas within a
handful of countries, as exemplifıed by the Garki study
conducted in northern Nigeria in the early 1970s.10,11
Although such studies provide vitally important infor-
mation on the natural history of SCD in these selected
areas, they do not shed light on how the burden of SCD
mortality might have changed over time as medical care
and public health have improved. There are some data to
suggest that survivalmight be improving. For example, in
a study conducted in Lusaka, Zambia, Athale and Chintu
reported that the case-fatality rate among children with
SS who were admitted to the University Teaching Hospi-
tal decreased from 18.6% in 1970 to 6.6% during 1987–
1989.53 Nevertheless, it is very likely that the majority of
hildren with SS in rural Africa still die during childhood
ccording to contemporary evidence from recent cross-
ectional studies, including research papers from central
urkina Faso by Simpore et al.,40 the Nyanza province of
Kenya by Desai et al.,48 the Kilifı district in coastal Kenya
by Williams et al.,41 and from the Northern region of
hana by Danquah et al.47 Although prospective cohort
tudies by Aidoo et al.43 and Kreuels et al.44 fromwestern
enya and southern Ghana, respectively, indicated little
xcess mortality among homozygotes, such data may not
eneralizable, given the likelihood that enrollment into
rospective cohort studies will raise the probability of
urvival.
Applied epidemiologic research on SCD and child sur-
ival among a variety of African populations is needed.
rospective intervention studies aimed at preventing
orbidity and mortality associated with SCD within the
ontext of African primary healthcare systems are ur-
ently needed. Such studies should carefully document
nd evaluate the specifıc services provided and the cost of
elivering such services in order to evaluate the scalability
f interventions of proven effıcacy. Although prospective
ohort studies are useful for studying morbidity, they are
ostly to undertake and limited in scope and generaliz-
bility, making it unlikely that many will be conducted.41
ecember 2011More critically, because the clinical facilities and care
available to children in such studies are much better than
the medical services received by the general pediatric
population, the survival rates observed among children
enrolled in such studies are also likely to be much higher.
Close medical supervision is itself an intervention.
The alternative to cohort studies is cross-sectional ob-
servational studies. Such studies have the advantage of
studying the actual situation of child survival under pre-
vailing conditions. However, in an age of proven life-
saving value of antimicrobial prophylaxis, children with
SCD discovered or recruited by organized research stud-
ies in Africa should be provided such therapy. It is not
ethically acceptable to watch such children get infected
and die from preventable causes without intervening.
The same constraint does not apply to the re-use of spec-
imens or data collected from studies fıelded for other
purposes. Creative approaches to the analysis of cross-
sectional data from existing, large, representative surveys
are needed.
Better data on the birth frequencies of SS and SC in
Africa are needed. Frequencies of S alleles can vary
considerably over relatively small distances (Figure 1).24
For example, pilot newborn screening studies in the
Democratic Republic of the Congo have indicated that
the frequency of SS at birth varies by region from 0.8% to
1.7%,54 and in neighboring Rwanda and Burundi, the
frequency is considerably lower, 0.1% or less.55,56 Never-
heless, too few surveys have been conducted to allow for
he estimation of birth frequencies for the whole of Af-
ica.26 Large numbers of newborns need to be screened to
stimate these frequencies with precision. An example of
uch a large-scale newborn screening has been conducted
n Kumasi, Ghana, since 1993;57 its expansion to the rest
f the country is expected to result in a large life-saving
enefıt.20
Conclusion
Sickle cell disease is an important but largely neglected
risk to child survival in most African countries. Action is
needed on at least two fronts. First, and most important,
public health programs including newborn screening,
health education, and immunization are urgently needed
on the model of pilot programs already being conducted
in Benin and Ghana.21,57 Careful collection and analysis
of data and publication of outcomes among children
affected by these programs are essential. Second, studies
to quantify the public health burden of SCD need to be
conducted. Such studies require interdisciplinary collab-
oration among different types of researchers and cooper-
ation among different public health programs conduct-
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nutrition, and HIV/AIDS.
In our view, themost effıcient and feasible approach to
studying the effect of SCD on child survival in Africa is to
use reliable, inexpensive laboratory methods with blood
specimens routinely collected in large national surveys,
such as national nutrition or AIDS indicator surveys. It is
important that different regions and both rural and urban
populations be represented. The frequency of survival
among African children born with SCD appears to be
highly variable by time and place, consistent with obser-
vations made by Jacob34 more than 50 years ago. The
probability of early death among children bornwith SS in
sub-Saharan Africamight be as high as 90% in rural areas
where access to health care is limited, but closer to 50% in
populations with better access to health care and lower
exposure to infectious diseases.
We suggest that greater attention to reducingmortality
from SCD could help some African governments to
achieve their targets with regard toMillenniumDevelop-
ment Goal (MDG) number 4: to reduce their under-5
mortality rates by two thirds during 1990–2015.58 A re-
cent progress report noted that although under-5mortal-
ity in sub-Saharan Africa has declined by 28% since 1990,
the rate of improvement is insuffıcient tomeet theMDG4
target. SCDmight be responsible for 5%–16% of under-5
mortality in some areas of sub-Saharan Africa according
to published estimates.59 Areas of high frequency of the
S allele, shown in dark shading in Figure 1, indicate
here homozygous SCD is a major public health prob-
em. As basic public health measures—including im-
roved nutrition and interventions against malaria,
neumonia, and diarrhea—reduce the burden of infec-
ious diseases, it is likely that the absolute burden of
ortality attributable to SCD will decrease, but that the
elative burden as a fraction of all under-5 mortality ac-
ually might rise.5
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